Key facts
- Shuangxing Pharmaceutical’s last known valuation is $63.3M (Feb 2025).
- It has raised $2.9M; the latest was Later Stage VC ($1.4M) in Feb 2025.
- Notable investors include GGR Capital, Hengbang Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Shuangxing Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Shuangxing Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Shuangxing Pharmaceutical
Provider, developer and manufacturer of medical materials and products designed for biological medicine, fine chemical and implantable medical devices. The company develops inorganic bioactive bone repair filling material, bioactive glass and dental fiber implant, enabling clients with medical materials.
- Sector
- Healthcare
- HQ
- Suizhou, China
- Founded
- 2013
- Employees
- 49
- Website
- hbsxyy.cn/
- Ownership
- Privately Held (backing)
Shuangxing Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Shuangxing Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Shuangxing Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.